Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium.
Epstein–Barr virus
kidney transplant
pediatrics
post‐transplant lymphoproliferative disorder
rituximab
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
revised:
16
02
2024
received:
13
11
2023
accepted:
05
03
2024
medline:
3
4
2024
pubmed:
3
4
2024
entrez:
3
4
2024
Statut:
ppublish
Résumé
There are scant data on the effect of rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplant recipients with EBV DNAemia. Kidney transplant recipients with EBV DNAemia treated with rituximab to prevent PTLD between 7/1999 and 7/2019 at five pediatric centers were included. Those with confirmed PTLD at the onset of rituximab were excluded. Primary outcomes included percentage change in EBV DNAemia and occurrence of PTLD post rituximab. Twenty-six pediatric kidney transplant recipients were included. Median age at transplant was 4 years (IQR 2.1-10.3). EBV DNA load monitoring by qPCR was performed at 1-3 month intervals. EBV DNAemia onset occurred at a median of 73 days post-transplant (IQR 52-307), followed by DNAemia peak at a median of 268 days (IQR 112-536). Rituximab was administered at a median of 9 days post peak (IQR 0-118). Rituximab regimens varied; median dose 375 mg/m In the largest pediatric kidney transplant recipient case series with EBV DNAemia given rituximab to prevent PTLD, rituximab achieved a short-term reduction in DNA load; however, recurrent DNAemia is common.
Sections du résumé
BACKGROUND
BACKGROUND
There are scant data on the effect of rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplant recipients with EBV DNAemia.
METHODS
METHODS
Kidney transplant recipients with EBV DNAemia treated with rituximab to prevent PTLD between 7/1999 and 7/2019 at five pediatric centers were included. Those with confirmed PTLD at the onset of rituximab were excluded. Primary outcomes included percentage change in EBV DNAemia and occurrence of PTLD post rituximab.
RESULTS
RESULTS
Twenty-six pediatric kidney transplant recipients were included. Median age at transplant was 4 years (IQR 2.1-10.3). EBV DNA load monitoring by qPCR was performed at 1-3 month intervals. EBV DNAemia onset occurred at a median of 73 days post-transplant (IQR 52-307), followed by DNAemia peak at a median of 268 days (IQR 112-536). Rituximab was administered at a median of 9 days post peak (IQR 0-118). Rituximab regimens varied; median dose 375 mg/m
CONCLUSIONS
CONCLUSIONS
In the largest pediatric kidney transplant recipient case series with EBV DNAemia given rituximab to prevent PTLD, rituximab achieved a short-term reduction in DNA load; however, recurrent DNAemia is common.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14743Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post‐transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016;2:15088. doi:10.1038/nrdp.2015.88
Dharnidharka VR, Lamb KE, Gregg JA, Meier‐Kriesche HU. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States. Am J Transplant. 2012;12(4):976‐983. doi:10.1111/j.1600-6143.2011.03893.x
Lentine KL, Smith JM, Miller JM, et al. OPTN/SRTR 2021 annual data report: kidney. Am J Transplant. 2023;23(2 Suppl 1):S21‐S120. doi:10.1016/j.ajt.2023.02.004
San‐Juan R, Manuel O, Hirsch HH, et al. Current preventive strategies and management of Epstein‐Barr virus‐related post‐transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH questionnaire‐based cross‐sectional survey. Clin Microbiol Infect. 2015;21(6):604e1–9. doi:10.1016/j.cmi.2015.02.002
Green M, Squires JE, Chinnock RE, et al. The IPTA Nashville consensus conference on post‐transplant lymphoproliferative disorders after solid organ transplantation in children: II‐consensus guidelines for prevention. Pediatr Transplant. 2022;28:e14350. doi:10.1111/petr.14350
Allen UD, Preiksaitis JK, Practice ASTIDCo. Post‐transplant lymphoproliferative disorders, Epstein‐Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation infectious diseases Community of Practice. Clin Transplant. 2019;33(9):e13652. doi:10.1111/ctr.13652
van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein‐Barr virus‐lymphoproliferative disease by molecular monitoring and preemptive rituximab in high‐risk patients after allogeneic stem cell transplantation. Blood. 2002;99(12):4364‐4369. doi:10.1182/blood.v99.12.4364
Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG. Monitoring and preemptive rituximab therapy for Epstein‐Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2010;16(2):287‐291. doi:10.1016/j.bbmt.2009.10.008
van der Velden WJ, Mori T, Stevens WB, et al. Reduced PTLD‐related mortality in patients experiencing EBV infection following allo‐SCT after the introduction of a protocol incorporating pre‐emptive rituximab. Bone Marrow Transplant. 2013;48(11):1465‐1471. doi:10.1038/bmt.2013.84
Martin SI, Dodson B, Wheeler C, Davis J, Pesavento T, Bumgardner GL. Monitoring infection with Epstein‐Barr virus among seromismatch adult renal transplant recipients. Am J Transplant. 2011;11(5):1058‐1063. doi:10.1111/j.1600-6143.2011.03478.x
Puliyanda DP, Jordan SC, Kim IK, et al. Use of rituximab for persistent EBV DNAemia, and its effect on donor‐specific antibody development in pediatric renal transplant recipients: a case series. Pediatr Transplant. 2021;25(8):e14113. doi:10.1111/petr.14113
Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629‐637. doi:10.1681/ASN.2008030287
Dharnidharka VR. Comprehensive review of post‐organ transplant hematologic cancers. Am J Transplant. 2018;18(3):537‐549. doi:10.1111/ajt.14603
Sinha R, Agrawal N, Xue Y, et al. Use of rituximab in paediatric nephrology. Arch Dis Child. 2021;106(11):1058‐1065. doi:10.1136/archdischild-2020-321211
Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169. doi:10.1001/jamanetworkopen.2018.4169
Bernard J, Sellier‐Leclerc AL, Demede D, Chamouard V, Ranchin B, Bacchetta J. Rituximab as induction therapy in pediatric kidney transplantation: a single‐center experience in four patients. Pediatr Transplant. 2022;26(6):e14329. doi:10.1111/petr.14329
Walti LN, Mugglin C, Sidler D, et al. Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): a nationwide cohort study. Am J Transplant. 2021;21(7):2532‐2542. doi:10.1111/ajt.16423